Raphael Pharmaceutical Inc.
RAPH
Other OTC1.40
USD
- -
- -
CIK
0001415397
ISIN
US27785B2088
CUSIP
27785B208
Return %
Stock
S&P500
1Y
315.43
26.57
3Y
-30.00
76.60
5Y
-36.36
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shlomo Pilo
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4 Lui Paster Jaffa Israel 6803605
- IPO Date
- Jan 5, 2023
- CIK
- 0001415397
- Website
- raphaelpharmaceutical.com
- Similar Companies
- Business
- Raphael Pharmaceutical Inc. (RAPH) is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil; its lead product candidate, Highly Purified Cannabinoid (HPC1), targets rheumatoid arthritis (RA), where the company has successfully completed proof-of-concept clinical trials; the company also develops cannabinoid-based formulations for autoimmune diseases and chronic lung inflammation, such as strain CBX to reduce cytokine storms published in Frontiers in Immunology; it investigates proprietary strains for oncology patients to address cancer treatment side effects including cachexia, fatigue, anemia, pain and depression through personalized therapies targeting cannabinoid receptors; and it pursues Phase 2 FDA approval and EMA clearance via outsourced GMP manufacturing and global royalty-based distribution. Raphael Pharmaceutical partners with the Medical Cannabis Research and Innovation Center at Rambam Health Care Campus in Haifa, Israel, for RA, autoimmune and oncology research, and with Schneider Children's Medical Center of Israel for pediatric cancer palliative care. The company, founded in 2007 and headquartered in Tel Aviv, Israel, plans market entry in California, Oklahoma and Colorado with expansion to the United States, Canada and Europe. In recent developments, Raphael Pharmaceutical issued a letter to shareholders on November 17, 2025, announced RA clinical trial results and CitrusLabs partnership in January 2025, filed a provisional patent for neutrophil-dominant autoimmune diseases treatment, and reported cash reserves of $19,000 as of December 31, 2024, while seeking additional funding to advance its pipeline amid pre-clinical and clinical studies for RA and asthma.
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
Raphael Pharmaceutical Issues Letter to Shareholders